NewsBenzingaActinium Pharma To Present First‑In‑Human Phase 1 Study Of ATNM‑400, HER3-Targeted, Non-PSMA Radiotherapy, In Metastatic Castration‑Resistant Prostate Cancer, At ESMO Congress 2026 Actinium Pharma To Present First‑In‑Human Phase 1 Study Of ATNM‑400, HER3-Targeted, Non-PSMA Radiotherapy, In Metastatic Castration‑Resistant Prostate Cancer, At ESMO Congress 2026 Benzinga 2026.10.23 12:05 (GMT+0) Open on Benzinga Other news Fermi Has a New Plan for Growing Its Data Center Business. What That Means for FRMI Stock. ‘I Don’t Want You to Contribute to a Trump Account for a Child. Period’: Suze Orman Says Take the Free $1,000 and Your Employer’s $2,500, Then Stop. ARB Touches Four-Week Low as Losses Outpace Bitcoin and Ether Instacart reportedly discussed selling itself with DoorDash and Uber QUALCOMM’s Quarterly Earnings Preview: What You Need to Know eBay Earnings Preview: Innovation Tops GameStop Bid (NASDAQ:EBAY)
‘I Don’t Want You to Contribute to a Trump Account for a Child. Period’: Suze Orman Says Take the Free $1,000 and Your Employer’s $2,500, Then Stop.
